High Expression of Urokinase-Type Plasminogen Activator Is Associated with Lymph Node Metastasis of Invasive Ductal Carcinoma of the Breast

다국어 초록 (Multilingual Abstract)

Purpose: In the present study, we evaluated the levels of urokinase- type plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1) by performing immunohistochemical staining to determine whether they were reliable prognostic markers in patients with breast cancer. Methods: Demographic and clinicopathological parameters of 214 patients with invasive ductal carcinoma (IDC) and 80 patients with ductal carcinoma in situ (DCIS) who were diagnosed and treated from 2006 to 2010 were analyzed. Tissue microarray was constructed and immunohistochemical staining was performed for each specimen. Results: Univariate analyses showed that age at diagnosis, history of hormone replacement therapy, radiation therapy, skin and chest wall invasion, Paget disease, lymphovascular invasion, estrogen receptor positivity, and triple-negative subtype were significantly associated with patient prognosis (p<0.005). Patients with DCIS showed higher PAI-1 expression than patients with IDC (82.5% and 36.2%, respectively; p=0.012). Lymph node metastasis was more frequent in patients with high uPA levels than in patients with low uPA levels (p=0.001). Conclusion: Our results suggested that PAI-1 was involved in tumor progression in the early stages of breast cancer, such as DCIS. In addition, our results suggested that high uPA levels were associated with the lymph node metastasis of IDC.

참고문헌 (Reference)

1 Malinowsky K, "uPA and PAI-1-related signaling pathways differ between primary breast cancers and lymph node metastases" 5 : 98-104, 2012

2 Duffy MJ, "uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies" 16 : 428-, 2014

3 Lamy PJ, "Urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 mRNA assessment in breast cancer by means of NASBA: correlation with protein expression" 128 : 404-413, 2007

4 Duffy MJ, "Urokinase-plasminogen activator, a marker for aggressive breast carcinomas:preliminary report" 62 : 531-533, 1988

5 Duffy MJ, "The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer" 37 : 541-548, 2004

6 Tang L, "The urokinase plasminogen activator system in breast cancer invasion and metastasis" 67 : 179-182, 2013

7 Harbeck N, "Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients" 49 : 1825-1835, 2013

8 Remmele W, "Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue" 8 : 138-140, 1987

9 Jänicke F, "Randomized adjuvant chemotherapy trial in high-risk, lymph nodenegative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1" 93 : 913-920, 2001

10 Duffy MJ, "Proteases as prognostic markers in cancer" 2 : 613-618, 1996

11 Kantelhardt EJ, "Prospective evaluation of prognostic factors uPA/PAI-1 in nodenegative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel" 11 : 140-, 2011

12 Saadoun H, "Prognostic impact of the inclusion of uPA/PAI-1 tumor levels in the current adjuvant treatment decision-making for early breast cancer" 10 : 195-209, 2014

13 Look MP, "Pooled analysis of prognostic impact of urokinasetype plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients" 94 : 116-128, 2002

14 Castelló R, "Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity" 117 : 487-492, 2006

15 Lei H, "PAI-1 -675 4G/5G polymorphism as a prognostic biomarker in breast cancer" 109 : 165-175, 2008

16 Lang DS, "Optimized immunohistochemistry in combination with image analysis: a reliable alternative to quantitative ELISA determination of uPA and PAI-1 for routine risk group discrimination in breast cancer" 22 : 736-743, 2013

17 Isaacs C, "New prognostic factors for breast cancer recurrence" 28 : 53-67, 2001

18 Haas S, "Influence of preoperative core biopsies on uPA/PAI-1 expression in breast cancer tissue" 452 : 277-283, 2008

19 Hansen S, "Independent prognostic value of angiogenesis and the level of plasminogen activator inhibitor type 1 in breast cancer patients" 88 : 102-108, 2003

20 Christensen L, "Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas" 66 : 441-452, 1996

21 Roca C, "Hyperthermia inhibits angiogenesis by a plasminogen activator inhibitor 1-dependent mechanism" 63 : 1500-1507, 2003

22 Bajou K, "Hostderived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth" 23 : 6986-6990, 2004

23 Andres SA, "Expression of urokinase-type plasminogen activator (uPA), its receptor (uPAR), and inhibitor (PAI-1) in human breast carcinomas and their clinical relevance" 26 : 93-103, 2012

24 Soff GA, "Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model" 96 : 2593-2600, 1995

25 Dass K, "Evolving role of uPA/uPAR system in human cancers" 34 : 122-136, 2008

26 Leik CE, "Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis" 4 : 2710-2715, 2006

27 Ferrier CM, "Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue" 79 : 1534-1541, 1999

28 Jänicke F, "Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer" 17 : 303-312, 1991

29 Schmitt M, "Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1" 11 : 617-634, 2011